tyrphostin ag 1024 has been researched along with imatinib mesylate in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bonnet, ML; Bourhis, J; Deutsch, E; Frascogna, V; Khanfir, K; Maggiorella, L; Turhan, AG; Wen, B | 1 |
1 other study(ies) available for tyrphostin ag 1024 and imatinib mesylate
Article | Year |
---|---|
Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; DNA-Activated Protein Kinase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Erythroblastic, Acute; Mice; Mice, Nude; Neoplasm Recurrence, Local; Nuclear Proteins; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Tumor Cells, Cultured; Tyrphostins | 2004 |